Recent News & Events
-
2019
-
2018
-
2017
-
2016
<
>
|
Apr
29 |
Olatec’s lead compound, dapansutrile, referenced in Nature Reviews Immunology publication entitled, ”The NLRP3 inflammasome: molecular activation and regulation to therapeutics"
Read More |
|
Mar
31 |
Charles Dinarello MD, CSO and Chairman of Olatec’s Scientific Advisory Board presents select data on dapansutrile at the 10th Biannual Meeting of the International Society of Systemic Auto-Inflammatory Diseases (ISSAID) in Genoa, Italy.
|
|
Mar
21 |
Olatec’s lead compound, dapansutrile, referenced in The Journal of Organic Chemistry publication entitled, "Discovery of Quinazolin-4(3H)-ones as NLRP3 Inflammasome Inhibitors: Computational Design, Metal-free Synthesis and In-vitro Biological Evaluation”
Read More |
|
Mar
4 |
Olatec’s lead compound, dapansutrile, referenced in Kidney International publication entitled, “Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases”
Read More |
|
Feb - Mar
28-2 |
Viola Klück PhD, presents two posters, covering the interim data generated in Olatec's recently completed Phase 2a safety & efficacy study of dapansutrile in patients with acute gout, entitled "The first phase 2a proof-of-concept study of a selective NLRP3 inflammasome inhibitor, OLT1177™ dapansutrile, in acute gout" and "OLT1177™ dapansutrile, an oral NLRP3 inflammasome inhibitor, inhibits acute joint inflammation and circulating IL‑1β during gout flares in humans" at the 39th European Workshop for Rheumatology Research (EWRR) Conference in Lyon, France.
|
|
February
12 |
Olatec’s lead compound, dapansutrile, referenced in Nature Cell Death & Disease publication entitled, “Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors”
Read More |
|
February
10 |
Timotheus L.Th.A. Jansen, MD PhD joins and becomes Chairman of the Olatec Clinical Advisory Board. Mr. Jansen has been contributing leading expertise in the design and conduct of Olatec’s human clinical trials in gout including serving as the principal investigator of the first clinical trial with dapansutrile for acute gout flares.
See Bio |
|
February
8 |
Olatec manuscript published in Journal of Cardiovascular Pharmacology entitled, "The NLRP3 Inflammasome Inhibitor, OLT1177™ (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse”
Read More |
|
December
21 |
Olatec’s lead compound, dapansutrile, referenced in Cardiovascular Research publication entitled, “Innate immunity as a target for acute cardioprotection”
Read More |
|
December
17 |
Olatec’s lead compound, dapansutrile, referenced in International Immunopharmacology publication entitled, “Role of pyroptosis in cardiovascular disease”
Read More |
|
December
11 |
Olatec’s lead compound, dapansutrile, referenced in Journal of Inflammation Research publication entitled, “Inflammasomes: Pandora’s box for sepsis”
Read More |
|
December
4 |
Olatec’s lead compound, dapansutrile, referenced in Frontiers in Neurology publication entitled, “Rusty Microglia: Trainers of Innate Immunity in Alzheimer's Disease”
Read More |
|
November
21 |
Bob Fielding joins the Olatec Scientific Advisory Board. Mr. Fielding is contributing leading expertise in the design and conduct of Olatec’s pharmacology programs. Mr. Fielding has over 30 years experience in the pharmaceutical and biotech industries, including with formulation evaluation, preclinical pharmacokinetics/toxicokinetics, pharmacology and clinical pharmacokinetic studies for more than 30 products now approved or in clinical trials.
See Bio |
|
November
21 |
Steve Newhard joins the Olatec Scientific Advisory Board. Mr. Newhard has over 40 years of experience in the pharmaceutical and regulatory industry and is responsible for manufacturing of Olatec's Lead Compound at CMOs producing the active drug substance and drug product.
See Bio |
|
November
14 |
Olatec’s lead compound, dapansutrile, referenced in Archives of Biochemistry & Biophysics publication entitled, “Development of covalent NLRP3 inflammasome inhibitors: Chemistry and biological activity”
Read More |
|
October
18 |
Olatec’s lead compound, dapansutrile, referenced in Clinical Rheumatology publication entitled, “Early canakinumab therapy for the sensorineural deafness in a family with Muckle-Wells syndrome due to a novel mutation of NLRP3 gene”
Read More |
|
September
5-7 |
Charles Dinarello MD, CSO and Chairman of Olatec’s Scientific Advisory Board, and Leo Joosten PhD, Olatec SAB Member, presents select data on dapansutrile at the New Frontiers in Innate Immunity & Inflammation in Cluj Napoca, Romania.
|
|
August
31 |
Olatec referenced in American Journal of Physiology-Heart and Circulatory Physiology publication entitled, “Inflammasome, Pyroptosis, and Cytokines in Myocardial Ischemia-Reperfusion Injury”
Read More |
|
August
14 |
Olatec’s lead compound, dapansutrile, referenced in Psychoneuroendocrinology publication entitled, “Emerging role of the P2X7-NLRP3-IL1β pathway in mood disorders”
Read More |
|
August
3 |
Olatec manuscript published in Arthritis Research & Therapy entitled, "NLRP3 inflammasome inhibitor OLT1177™ suppresses joint inflammation in murine models of acute arthritis”
Read More |
|
July
20 |
Olatec’s lead compound (OLT1177™ dapansutrile) referenced in Nature Reviews Drug Discovery publication entitled, "Targeting the NLRP3 inflammasome in inflammatory diseases”
Read More |
|
April
4 |
Olatec referenced in Nature Scientific Reports publication entitled,"Development of a characterised tool kit for the interrogation of NLRP3 inflammasome-dependent responses”
Read More |
|
March
1 |
Charles Dinarello MD, CSO and Chairman of Olatec’s Scientific Advisory Board, presents select data on dapansutrile at the European Crystal Network Workshop in Paris, France.
|
|
February
23 |
Olatec referenced in European Heart Journal, published on behalf of European Society of Cardiology, entitled, "Interleukin-1 blockade in cardiovascular diseases: a clinical update”
Read More |
|
January
29 |
Olatec’s research manuscript published in Proceedings of the National Academy of Sciences, entitled "OLT1177™ , a β‑sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation”.
Read More |
|
January
9 |
Robert Barrow, presents Olatec at Biotech Showcase ™ 2018 in San Francisco, CA. Biotech Showcase ™ is an investor conference during the J.P. Morgan Annual Healthcare Conference, one of the industry's largest annual healthcare investor conferences
|
|
June
14 |
Carlo Marchetti, PhD, Director for Olatec’s Innovative Science Program in Dr. Charles Dinarello’s Laboratory, presents, “The Human Safe NLRP3 Inflammasome Inhibitor OLT1177™ Suppresses Joint Inflammation in Murine Models of Experimental Arthritis” at EULAR conference in Madrid, Spain
|
|
April
21 |
Carlo Marchetti, PhD, Director for Olatec’s Innovative Science Program in Dr. Charles Dinarello’s Laboratory, presents poster, “The Novel and Safe Pharmaceutical Compound OLT1177™ Reduces Inflammation by Preventing Activation of the NLRP3 inflammasome” at AAP/ASCI/APSA Meeting in Chicago, IL
|
|
March
19 |
Antonio Abbate, MD, PhD joins the Olatec Scientific Advisory Board. Dr. Abbate is a prominent leader in the field of cardiovascular disease
|
|
November
16 |
Olatec referenced in Nature Reviews Cardiology entitled, "The NLRP3 inflammasome in acute myocardial infarction”
|
|
November
12 |
Stefano Toldo, PhD, Virginia Commonwealth University Assistant Professor, Department of Internal Medicine Division of Cardiology, presents poster, “Novel NLRP3 Inflammasome Inhibitor OLT1177™ Reduces Infarct Size in a Mouse Model of Myocardial Ischemia Reperfusion Injury” at the AHA conference in Anaheim, CA
|
|
October
11 |
Olatec referenced in Nature Biotechnology entitled, “Novartis trial validates inflammasome as chronic disease driver”
|
|
November
27 |
Franz Hefti, PhD joins the Olatec Scientific Advisory Board. Dr. Hefti is a prominent leader in the development of neurodegenerative therapeutics and an experienced biotech CEO
|